Inflammatory bowel disease and risk of more than 1500 comorbidities: A disease-wide pre- and post-diagnostic phenomic association study

Anthony C Ebert[1*], Rahma Elmahdi[1,2*], Bram Verstockt[3,4], Martin Bøgsted[1], Gry Poulsen[1], Aleksejs Sazonovs[1], Charlie W Lees[5**], and Tine Jess[1,2**]

[1]Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark

[2]Department of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, Denmark

[3]Department of Gastroenterology and Hepatology, University Hospitals Leuven, KU Leuven, Leuven, Belgium

[4]Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium

[5]Centre for Genomic and Experimental Medicine, Institute of Genetics and Cancer, University of Edinburgh, UK

[*]Co-first author

[**]Denotes joint last authorship

Correspondence
Anthony C Ebert
Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT)
Department of Clinical Medicine, Aalborg University
A.C. Meyers Vænge 15, Copenhagen SV, 2450, Denmark
email: anthonyce@dcm.aau.dk

ABSTRACT

Introduction: Inflammatory bowel disease (IBD) is associated with various extra-intestinal manifestations. We aim to identify comorbidities in IBD and the timing of their development to provide valuable insight into the mechanisms underlying IBD.

Methods: We conducted a population- and disease-wide phenomic association study in IBD, using >6 million ICD-10 coded healthcare contacts from 10 years before and up-to 17 years after IBD diagnosis to investigate associations with 1583 comorbidities. To explore diseases with potential aetiological significance, we compared association in the pre-diagnostic and the post-diagnostic periods. We corrected also for multiple-testing. These estimates were validated with publically available data from Finland.

Results: We identified 312 significant associations with 125 appearing before diagnosis. Risk of immune-mediated diseases and extra-intestinal manifestations was increased up to 10 years prior to IBD diagnosis, such as psoriasis (OR_{CD}: 2.58 95% CI: [2.00-3.31]; OR_{UC}: 1.54 [1.26-1.88]) and reactive arthropathies (OR_{CD}: 2.07 [1.42-2.96]; OR_{UC}: 1.42 [1.08-1.84]). Risk of cardiometabolic and neuropsychological disorders was increased both pre- and post-diagnostically. Potential treatment sequelae, such as osteoporosis (HR_{CD}: 2.56 [2.30-2.86]; HR_{UC}: 1.92 [1.79-2.07]) were primarily seen post-diagnostically. In only 15.7% (44/281) and 11.4% (35/301) of comorbidities in CD and UC respectively did we observe heterogeneity between Denmark and Finland.

Conclusion: Findings demonstrate that IBD is a multisystemic disease, particularly manifesting with metabolic, immune, and neuropsychological disorders, up-to 10 years prior to diagnosis. We find evidence for the generality of these findings with an international comparison. Diseases of etiological interest warrant further investigation.

STUDY HIGHLIGHTS

WHAT IS KNOWN

- IBD is strongly associated with other diseases
- IBD has a complex etiology

WHAT IS NEW HERE

- IBD appears to be a multiorgan systemic disease not confined to the gut
- Associations between IBD and non-digestive disorders are present up to 10 years prior to diagnosis either reflecting a prolonged pre-diagnostic phase or common etiologies
- These findings are validated in an international comparison

1 INTRODUCTION

The inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are chronic intestinal conditions with a multifactorial etiology. Identified genetic risk loci[1;2] may —in combination with environmental factors, such as diet, smoking, exercise, and exposure to infectious agents—be implicated in disease development[3] through multiple mechanisms, including epigenetic modifications, alterations in the gut microbiota, and immune dysregulation[4]. To complicate the aetiological understanding of IBD further, between 6-50% of patients develop extra-intestinal manifestations (EIMs), including erythema nodosum, uveitis, primary sclerosing cholangitis, and autoimmune hepatitis[5], or immune-mediated inflammatory diseases (IMIDs), including psoriasis and ankylosing spondylitis, which may share common inflammatory pathways, genetic associations[6], and response to anti-inflammatory therapies including those targeting TNF, IL12/23, and JAK inhibition. Emerging evidence also suggests that neuropsychiatric diseases[7] and cardiovascular diseases occur with increased frequency in IBD[8], and additional diseases may occur either due to chronic inflammation, altered immunity and/or treatment with corticosteroids and immunosuppression[9].

Hence, our understanding of IBD as a single-organ disease is challenged, while evidence of the involvement of other organs is still fragmented. This creates limitations for our aetiological understanding of IBD and the ability to optimize disease phenotyping and tailor treatment.[10] In other IMIDs, such as rheumatoid arthritis and psoriasis, there in increasing systematic investigation into associated comorbidities, primarily those manifesting following IMID diagnosis. This has not only enhanced the understanding of disease etiology of diseases such as rheumatoid arthritis and psoriasis but has also revealed that co-morbidities lead to increased cost of care, poorer medical outcomes,[11;12] and reduced emotional functioning[13]. With a compounding prevalence of IBD worldwide and an increasing average age of IBD patients[14], the co-morbid burden is only expected to increase further, and a greater understanding of the interrelationship of IBD and comorbid diseases is urgently needed.

Using Danish nationwide healthcare data on all disease categories, as defined by the World Health Organization's 10th revision of the International Classification of Diseases (ICD-10), we aimed to undertake the first population- and

disease-wide association study in IBD exploring all pre-diagnostic comorbidities from 10 to 1 year prior to IBD, as well as all post-diagnostic comorbidities observed from date of IBD diagnosis and up to 17 years after.

2 METHODS

2.1 Data and study population

The Danish National Patient Register (LPR) covers the entire population of Denmark with comprehensive data from 1977[15]. These data record hospital contacts with associated diagnostic codes including outpatient contacts from 1995 and contacts from private hospitals from 2002. IBD and all other diseases are defined with reference to the World Health Organization's 10th revision of the International Classification of Diseases (ICD-10)[16]. The LPR data are linked to the Danish Civil Registration System (CPR)[17] by a unique personal identification number to verify and obtain data on age, sex, vital statistics, and residence.

The study cohort comprises all Danish residents with a new IBD diagnosis in the period from 1 January 2005 to 31 December 2021. IBD cases are identified with reference to the LPR with the following criteria, as established in a previous study[18], at least two in- or outpatient contacts within a two-year period, with associated (primary or secondary) IBD diagnostic codes (CD: ICD-8 563.01, 563.02, 563.08, 563.09 and ICD-10: K50; UC: ICD-8 563.19, 569.04 and ICD-10 codes K51). Patients with an earlier in- or out-patient contact with an IBD diagnostic code were excluded. A case is defined as either UC or CD based on the most recent diagnostic code and the date of first recorded diagnosis is termed the index-date. To allow adequate time to identify pre-diagnostic comorbidities and to improve identification of only newly diagnosed IBD cases, the IBD patients included must be continuously resident in Denmark for at least 10 years prior to their index-date to be included as a case in the study. Demographic and residency data for cases and controls were retrieved from the CPR.

At the index date, each case is matched to six controls from the general Danish population by sex, date of birth and municipality of residence. Each control must also have been continuously resident in Denmark for at least 10 years prior to the index-date. Additionally, the controls must be resident in Denmark until the second in- or outpatient contact of their case, to avoid immortality bias. Finally, the control must be free of IBD diagnoses prior to the index-date. The study population was followed until a censoring event including emigration, death, 31 December 2021 (end of study), or any diagnosis of IBD (for matched controls).

2.2 Statistical analysis

We analyse the association between IBD and the 1583 diseases at the three-character level in Chapters (I-XIX) of ICD-10 (e.g., M72 *Fibroblastic disorders*). The analysis is split into two diagnostic windows (pre-diagnosis and post-diagnosis) for each three-character disease category. First, we calculate the cumulative incidence spanning from 10 years prior up to 10 years after the IBD diagnosis date for the first appearance of any diagnosis by disease category within each chapter. We then calculate pre- and post-diagnosis risk of ICD-10 disease category diagnosis and finally, calculate risk of pre-diagnosis association compared with post-diagnosis association of statistically significant disease categories with large effect size.

The IBD pre-diagnostic period is defined as the nine-year period from ten years prior to one year before the index-date. We exclude the most recent year prior to diagnosis from the pre-diagnostic period to avoid capturing sequelae of IBD management following diagnosis in the pre-diagnostic period. For each disease category, we record the number of cases and controls with that diagnosis in the pre-diagnostic period, perform Fisher's exact test to compute the p-value and calculate an odds ratio estimate (OR) with a confidence interval.

The post-diagnostic period is defined as the period immediately after diagnosis and ends at the point of censoring or ICD-10 disease category diagnosis. For each disease category, the study population comprises all IBD cases and controls without a prior diagnosis of the disease category in question. Therefore, all diagnoses within a disease category are the first for the case or the match. We perform Cox proportional regression analysis for ICD-10 disease category diagnosis to compute a hazard ratio (HR), 95% confidence interval and p-value.

To correct for multiple testing, we adjust our significance threshold (from $p<0.05$) with the Bonferroni correction[19]. We test 6332 disease associations (1583 disease categories for both CD and UC, in the pre- and post-diagnostic window) resulting in a Bonferroni adjusted p-value of 7.90×10^{-6}, which we refer to as the threshold for disease-wide statistical significance.

In the interest of identifying potential novel disease associations, comorbidities with disease-wide statistical significance (in either the pre- or post-diagnostic period) are further screened for prevalence threshold of at least 0.2% for assessment. We exclude categories with vague or catch-all terms such as "M89 *Other disorders of bone*". Certain estimates could not be reported due to anonymity requirements and low case numbers, in these cases the intervals are left blank in the figures.

Finally, we identify comorbidities with strong pre-diagnostic effects, relative to their post-diagnostic effects. This analysis includes only highly significant pre-diagnostic ($p< 0.001$) disease categories, where the ratio of pre- to post-diagnostic effect is greater than 1.2-fold.

To understand the generalizability of our findings based on Denmark's registries, we compare effect sizes for IBD associated comorbidities with those available through the Finnish electronic registry system (FinRegistry).[20] The effect estimates that we could obtain through this resource did not distinguish between the pre- and post-diagnostic windows, which is an important limitation, but it does allow us to validate estimates. For the purposes of computing comparable estimates, we did not distinguish between pre- and post-diagnostic windows in the validation subanalysis.

To identify heterogeneity in relationships between IBD and comorbidities in FinRegistry relative to the Danish registries, we use Breslow-Day's test with Tarone's correction[21] as implemented by the R package metafor.[22] Some FinRegistry estimates did not include counts for privacy reasons, so for these diseases we cannot assess heterogeneity. To identify systematic biases of the registries as to the size of odds ratios, we conduct a paired Wilcoxon signed rank test.[23]

3 RESULTS

We identified 11,298 CD patients and 23,067 UC patients diagnosed with IBD in Denmark in the period from 1 January 2005 to 31 December 2021. Each patient was matched to six individuals from the general Danish population by sex, date of birth and municipality (n = 206,190) using the date of diagnosis as index date (Figure S1). Among IBD patients, 56.4%

of CD patients and 51.7% of UC patients were women, 50.9% of CD patients and 40.3% of UC patients were diagnosed before age 40 (Table 1).

3.1 Cumulative incidence of comorbidities pre- and post-IBD

We observed an overall pattern of multimorbidity across organ systems, beginning up to 10 years prior to diagnosis and being increasingly pronounced over time. We particularly observe a significantly increased risk of cardiometabolic, neuropsychological, and skin and musculoskeletal disorders present up to a decade before IBD diagnosis (Figure 1). For most organ systems, the excess occurrence of diseases both pre- and post-diagnostically was more pronounced in CD than in UC (Figure 1; Figure S2).

Figures 2a and 2b illustrate the pre- and post-diagnostic risk of comorbidities for CD patients for ICD-10 chapter I to XI and XII to XIX, respectively. Whereas Figures 3a and 3b illustrate the pre- and post-diagnostic risk of comorbidities for UC patients for ICD-10 chapter I to XI and XII to XIX, respectively.

3.2 Pre- and post-diagnostic EIMs and IMIDs

We confirmed the occurrence of a series of EIMs after IBD diagnosis and were able to show that the majority of these EIMs already occurred in excess up to 10 years prior to IBD diagnosis, including diseases of the joints, eyes, skin, and respiratory tract. Joint and musculoskeletal disorders, such as reactive arthropathies, were seen at increased rates in both CD (OR: 2.07 95% CI: [1.42-2.96]) and UC (OR: 1.42 [1.08-1.84]) prior to IBD diagnosis, and even more pronounced after IBD diagnosis. Pyoderma gangrenosum was only increased prior to diagnosis in UC (OR_{UC}: 4.80 [1.65-13.50]), despite a markedly excess risk in CD after diagnosis (HR_{CD}: 29.40 [11.20-77.10]).

We confirmed an increased risk of multiple IMIDs in IBD patients versus the matched control population, and further showed that the increased risk was present up to 10 years prior to IBD diagnosis, as illustrated by estimates for psoriasis (OR_{CD}: 2.58 [2.00-3.31]; OR_{UC}: 1.54 [1.26-1.88]) and rheumatoid arthritis in CD (OR: 2.18 [1.69-2.80]).

3.3 Pre-diagnostic gastrointestinal and liver diseases

Several gastrointestinal and liver disorders, which were expected post-diagnostically, were already observed in excess in the pre-diagnostic period for both CD and UC. Diagnoses of chronic gastrointestinal diseases associated with IBD, including gastro-oesophageal reflux disease (OR_{CD}: 2.29 [1.98-2.64]; OR_{UC}: 1.65 [1.48-1.84]), gastric (OR_{CD}: 2.58 [2.04-3.24]; OR_{UC}: 1.68 [1.42-1.99]) and duodenal ulcers (OR_{CD}: 3.40 [2.47-4.64]; OR_{UC}: 0.98 [0.76-1.26]) showed stronger pre-diagnostic association with CD than UC. As expected, acute appendicitis prior to IBD diagnosis was associated with increased risk of CD (OR_{CD}: 1.60 [1.37-1.85]) and decreased risk of UC (OR_{UC}: 0.77 [0.66-0.90]).

3.4 Pre- and post-diagnostic cardiometabolic disorders

We observed an increased risk of cardiovascular diseases in the pre-diagnostic period, including hypertension (OR_{CD}: 1.46 [1.35-1.59]; OR_{UC}: 1.24 [1.17-1.31]) and ischemic heart disease (OR_{CD}: 1.29 [1.12-1.49]; OR_{UC}: 1.31 [1.20-1.42]) for both CD and UC, and arterial embolism and thrombosis (OR_{CD}: 2.16 [1.19-3.77]) in CD, which increased over time

in the post-diagnostic period. We furthermore observed an increased risk of type 2 diabetes mellitus both prior to (OR_{CD}: 1.34 [1.17-1.54]; OR_{UC}: 1.14 [1.04-1.24]) and after IBD diagnosis, as well as an increased risk of obesity, particularly in the post-diagnostic period (HR_{CD}: 1.46 [1.34-1.6]; HR_{UC}: 1.23 [1.15-1.32]).

3.5 Pre- and post-diagnostic neuropsychological disorders including substance use

Excess risk of several mental and behavioural disorders, including depression, anxiety, and substance use disorders was observed in the pre- and post-diagnostic period for CD patients in particular, who had a markedly increased risk of alcohol (HR: 1.54 [1.30-1.81]), tobacco use disorders (HR: 4.04 [3.51-4.65]), and stress and adjustment disorders (HR: 1.62 [1.40-1.87]) post-diagnostically.

All effect sizes calculated for comorbidities associated with CD and UC in the pre- and post-diagnostic period are presented in Table S1.

3.6 Disease risk in pre-diagnostic relative to post-diagnostic phase

Finally, we assessed which diseases were more prominent in the *pre-diagnostic* relative to the *post-diagnostic* period (Figure 4). Overall, there were more diseases occurring predominantly pre-diagnostically, compared to the post-diagnostically in patients with CD (14 diseases) than in patients with UC (10 diseases), confirming the more pronounced systemic prodromal development of CD and include expected diagnoses, such as haemorrhoids (OR: 2.59 [2.28-2.94]; HR: 1.81 [1.60-2.04]), as well as unexpected diagnoses, such as hypertension which was more prominent prior to diagnosis (OR: 1.46 [1.35-1.59]; HR: 1.17 [1.08-1.27]). Lastly, UC patients were at higher risk of being diagnosed with stress before compared with after UC diagnosis (OR: 1.41 [1.17-1.70]; HR: 1.08 [0.95-1.22]), potentially reflecting delayed diagnosis of IBD reflected by increased symptoms of deterioration.

3.7 Meta-analysis

To test our findings, we looked up all codes, presented in Figures 2-4 in the Finnish data (with the limitation that the Finnish estimates did not distinguish between the pre-diagnostic and post-diagnostic periods) and marked all estimates in Figures 2-4 with `(+FI)` if our associations were confirmed in the Finnish data. Further, direct comparison of Danish and Finnish effect sizes are shown in Figure 5, where we also indicate where there is evidence of inconsistency between Finland and Denmark, when corrected for multiple testing. Effects which were stronger in Denmark appear above the line, and effects which were stronger in Finland appear below the line.

There was evidence of heterogeneity of ORs between the two countries in only 15.7% (44/281) and 11.4% (35/301) of diseases in CD and UC respectively. In every disease except one, the directions of the effect size were consistent. The one exception was E78.0 Pure hypercholesterolaemia, where the Finnish data indicated a protective effect for IBD (OR_{CD}: 0.67 [0.60-0.67]; OR_{UC}: 0.82 [0.76-0.88]), whereas IBD was a risk factor in Denmark (OR_{CD}: 1.30 [1.18-1.42]; OR_{UC}: 1.25 [1.18-1.32]). We conducted a paired Wilcoxon signed rank test between the registry systems. Crohn's disease ORs were systematically higher in Denmark relative to Finland ($p < 1 \times 10^{-6}$), whereas there was no significant difference between effect sizes for Danish and Finnish patients with UC ($p = 0.203$).

4 DISCUSSION

This comprehensive population-based disease-wide association study examining >1500 diseases among >35,000 patients with IBD and >200,000 controls revealed that a diagnosis of IBD was associated with 312 other diseases, of which 125 diseases were present up to 10 years before diagnosis. Based on these observations, we created an interactive resource to explore IBD comorbidities across organ systems (Table S1). In addition to identifying expected diseases associated with IBD, including known EIMs and IMIDs, we identified multisystem comorbidities up to a decade prior to the incident IBD diagnosis, including cardiometabolic, neuropsychological, and immune and infectious diseases associated with both CD and UC. Most of the pre-diagnostic comorbidities appeared with larger effect sizes and earlier in CD than UC patients. Results were validated and confirmed with respect to publicly available (albeit cruder) Finnish estimates.

The validity of our findings is further confirmed by observation of an expected increased risk of EIMs in patients with IBD, including erythema nodosum, asthma, pyoderma gangrenosum, and iridocyclitis, as well as an increased risk of IMIDs, such as psoriasis, ankylosing spondylitis and coeliac disease.[24] In addition to showing the exact magnitude of these risks at a population level representing the true spectrum of IBD (from the mildest to the most severe case), hence providing estimates that can be used for information of newly diagnosed patients with a yet unknown disease course, we also show that these disorders are present at significantly increased frequency several years before diagnosis, pointing towards a long prodromal phase of IBD with multiorgan involvement. We observe that the risk of EIMs and IMIDs in the post-diagnostic period is larger in CD than in UC, again highlighting CD particularly as a multisystem disease. Our findings may have implications for screening and therapeutic considerations and raises the question, whether EIM and IMID diagnoses should prompt practitioner investigation for IBD in the context of gastrointestinal symptoms.

In addition to EIMs and IMIDs, we observe an increased risk of cardiometabolic disorders following IBD diagnosis in accordance with former observational studies[25;26]. We show that these diseases may be present up to a decade prior to IBD diagnosis, which may have both aetiological and treatment implications. The pre-IBD presence of cardiometabolic diseases indicates that not only chronic systemic inflammation, but also shared underlying mechanisms for development of cardiometabolic disease and IBD may exist, potentially reflecting shared environmental factors such as smoking and diet, which may act through microbiome dysfunction[3]. The increased risk of cardiometabolic disease in the pre-diagnostic period may also have clinical implications. The risk of ischaemic heart disease is increased markedly prior to IBD diagnosis and warrants clinical awareness following an IBD diagnosis. As JAK inhibitors – a class of small oral molecules to treat chronic inflammatory diseases - have recently been linked with increased MACE (major adverse cardiovascular events) risk–in rheumatoid arthritis populations[27], additional caution might also be warranted in selected IBD patients in light of our observed pre-diagnostic cardiovascular comorbidity.

Regarding the psychiatric disorders, we confirm significant bidirectional association between IBD in relation to depression and anxiety[28]. The proposed mechanisms underlying this association[7] are complex but may involve direct biochemical pathways through "the gut–brain axis" via the vagus nerve[29], or more indirect mechanisms, such as the, possibly preclinical, symptoms of IBD inducing psychological stress[30].

For several diseases primarily observed in excess following an IBD diagnosis, it remains to be understood if these are consequences of severe disease or the treatment thereof. Two recent meta-analyses[31;32] have demonstrated the harms

associated with placebo — and hence untreated active IBD — in randomized controlled trials, but consequences of treatment still merit attention. We observed a significantly increased risk in the post-diagnostic period of osteopenia and osteoporosis with pathological fracture, which is a well-documented adverse effect of long-term steroid exposure.[33] Advances in IBD therapies over the last decades with more steroid sparing management in severe IBD management may change this picture over time. In addition to active disease, immunosuppression may explain the viral enteric, pulmonary, and opportunistic infections seen at higher rates in the post- compared with pre-diagnostic period. Balancing the adverse impact of therapies is an ongoing clinical challenge, and there is also a need for development of tools to differentiate between severity of disease and consequences of treatment thereof when assessing long-term outcomes with observational data.

The Danish LPR and FinRegister are shown to be broadly consistent regarding the computed effect sizes of IBD on other comobidities. Heterogeneity in effect sizes is to be expected since there are country-level differences in the age-structure and censoring distributions.

The strengths of the present study are the population-wide and disease-wide assessment of all potential known and unknown comorbidities of IBD, which to our knowledge is the first phenomic study of this nature for any chronic illness. Further strengths are the size of the case population, assuring power; the drawing of matched controls from the general population rather than non-IBD hospital records, improving the generalizability of our findings; the length of follow-up beginning from 10 years prior to diagnosis until up to 17 years post-diagnosis, allowing us to investigate long-term associations in either direction of diagnosis; and the termination of the pre-diagnostic window 1 year prior to the incident diagnosis of IBD, thereby reducing surveillance bias. Lastly, both our application of a prevalence threshold of 0.2% for disease assessment and our choice of the Bonferroni correction, leading to a disease-wide significance threshold of 7.90×10^{-6}, reduces the potential for false positive findings.

Potential limitations that should be acknowledged include that registry data is subject to surveillance bias or capture of systemic biases such as common incorrect diagnoses by clinical practitioners, and this may have impacted our identification of several disorders diagnosed via e.g., endoscopy, including benign intestinal tumours or diverticular disease. Although we capture most EIMs and IMIDs associated with IBD and, as a novel finding, show that they appear many years prior to disease diagnosis, not all known IMIDs related to IBD will be captured, if not captured through outpatient or inpatient contacts. The study also contains risk of ascertainment bias, but this is be diminished by use of population-representative, nationwide diagnostic data, where cases are additionally matched to controls within municipality of residence. This is particularly the case for our findings in analyses from the pre-diagnostic period, where IBD patients would not be subject to the same level of clinical follow-up as following diagnosis.

In conclusion, in this population-based disease-wide study of almost 35,000 IBD patients followed for >300,000 pre-diagnostic and >250,000 post-diagnostic person-years (average 7.68 person-years per case), we observe an overall pattern of multimorbidity beginning from 10 years prior to diagnosis, with a more pronounced effect in CD relative to UC. Findings indicate the presence of multisystem pathology, which is increasing in frequency throughout the disease course. This underscores the need for multidisciplinary care, including cardiometabolic measurements and neuropsychological support, and increased attention to the management of a broad range of co-occurring disorders already present at the time of IBD diagnosis.

References

[1] Byong Duk Ye and Dermot PB McGovern. Genetic variation in IBD: progress, clues to pathogenesis and possible clinical utility. *Expert Rev. Clin. Immunol.*, 12(10):1091–1107, 2016.

[2] Isabelle Cleynen, Gabrielle Boucher, Luke Jostins, L Philip Schumm, Sebastian Zeissig, Tariq Ahmad, Vibeke Andersen, Jane M Andrews, Vito Annese, Stephan Brand, et al. Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. *Lancet*, 387(10014):156–167, 2016.

[3] Robert Carreras-Torres, Gemma Ibáñez-Sanz, Mireia Obón-Santacana, Eric J Duell, and Victor Moreno. Identifying environmental risk factors for inflammatory bowel diseases: a Mendelian randomization study. *Scientific reports*, 10 (1):19273, 2020.

[4] Daniel B Graham and Ramnik J Xavier. Pathway paradigms revealed from the genetics of inflammatory bowel disease. *Nature*, 578(7796):527–539, 2020.

[5] Hannah Gordon, Johan Burisch, Pierre Ellul, Konstantinos Karmiris, Konstantinos Katsanos, Mariangela Allocca, Giorgos Bamias, Manuel Barreiro-de Acosta, Tasanee Braithwaite, Thomas Greuter, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. *Journal of Crohn's and Colitis*, 18(1):1–37, 2024.

[6] Charlie W Lees, JC Barrett, M Parkes, and J Satsangi. New IBD genetics: common pathways with other diseases. *Gut*, 60(12):1739–1753, 2011.

[7] Tania H Bisgaard, Kristine H Allin, Laurie Keefer, Ashwin N Ananthakrishnan, and Tine Jess. Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. *Nat. Rev. Gastroenterol. Hepatol.*, 19(11):717–726, 2022.

[8] Julie Aarestrup, Tine Jess, Camilla J Kobylecki, Børge G Nordestgaard, and Kristine H Allin. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. *Journal of Crohn's and Colitis*, 13(3):319–323, 2019.

[9] Rahma Elmahdi, Louise T Thomsen, Aske T Iversen, Kristine H Allin, Susanne K Kjær, and Tine Jess. Increased risk of genital warts in inflammatory bowel disease: A Danish registry-based cohort study (1996–2018). *United Eur. Gastroenterol. J.*, 10(3):287–295, 2022.

[10] Marjorie Argollo, Daniela Gilardi, Carina Peyrin-Biroulet, Jean-Francois Chabot, Laurent Peyrin-Biroulet, and Silvio Danese. Comorbidities in inflammatory bowel disease: a call for action. *Lancet Gastroenterol. Hepatol.*, 4(8): 643–654, 2019.

[11] Premarani Sinnathurai, Rachelle Buchbinder, Catherine Hill, Marissa Lassere, and Lyn March. Comorbidity in psoriatic arthritis and rheumatoid arthritis. *Intern. Med. J.*, 48(11):1360–1368, 2018.

[12] Jin Bu, Ruilian Ding, Liangjia Zhou, Xiangming Chen, and Erxia Shen. Epidemiology of psoriasis and comorbid diseases: a narrative review. *Front. Immunol.*, 13(880201):2484, 2022.

[13] Joëlle Van Den Hoek, Leo D Roorda, Hendriek C Boshuizen, Gerard J Tijhuis, Geertrudis A Van Den Bos, and Joost Dekker. Physical and mental functioning in patients with established rheumatoid arthritis over an 11-year followup period: the role of specific comorbidities. *J. Rheumatol.*, 43(2):307–314, 2016.

[14] Stephanie Coward, Fiona Clement, Eric I Benchimol, Charles N Bernstein, J Antonio Avina-Zubieta, Alain Bitton, Mathew W Carroll, Glen Hazlewood, Kevan Jacobson, Susan Jelinski, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. *Gastroenterology*, 156(5):1345–1353, 2019.

[15] Morten Schmidt, Sigrun Alba Johannesdottir Schmidt, Jakob Lynge Sandegaard, Vera Ehrenstein, Lars Pedersen, and Henrik Toft Sørensen. The Danish National Patient Registry: a review of content, data quality, and research potential. *Clinical epidemiology*, 7:449–490, 2015.

[16] World Health Organization. *ICD-10 : international statistical classification of diseases and related health problems*, volume 2. World Health Organization Geneva, 10th revision, 5th ed. edition, 2004. ISBN 9241546492 9241546530 9241546549. URL `https://apps.who.int/iris/handle/10665/246208`.

[17] Morten Schmidt, Lars Pedersen, and Henrik Toft Sørensen. The Danish Civil Registration System as a tool in epidemiology. *Eur. J. Epidemiol.*, 29:541–549, 2014.

[18] Manasi Agrawal, Heidi S Christensen, Martin Bøgsted, Jean-Frederic Colombel, Tine Jess, and Kristine H Allin. The rising burden of inflammatory bowel disease in Denmark over two decades: a nationwide cohort study. *Gastroenterology*, 163(6):1547–1554, 2022.

[19] Tyler J VanderWeele and Maya B Mathur. Some desirable properties of the Bonferroni correction: is the Bonferroni correction really so bad? *Am. J. Epidemiol.*, 188(3):617–618, 2019.

[20] Essi Viippola, Sara Kuitunen, Rodosthenis S Rodosthenous, Andrius Vabalas, Tuomo Hartonen, Pekka Vartiainen, Joanne Demmler, Anna-Leena Vuorinen, Aoxing Liu, Aki S Havulinna, et al. Data resource profile: Nationwide registry data for high-throughput epidemiology and machine learning (FinRegistry). *Int. J. Epidemiol.*, 52(4):e195–e200, 2023.

[21] Robert E Tarone. On heterogeneity tests based on efficient scores. *Biometrika*, 72(1):91–95, 1985.

[22] Wolfgang Viechtbauer. Conducting meta-analyses in R with the metafor package. *J. Stat. Softw.*, 36(3):1–48, 2010.

[23] Frank Wilcoxon. Individual comparisons by ranking methods. *Biometrics*, 1(6):80–83, 1945.

[24] Charles N Bernstein, Zoann Nugent, Seth Shaffer, Harminder Singh, and Ruth Ann Marrie. Comorbidity before and after a diagnosis of inflammatory bowel disease. *Aliment. Pharmacol. Ther.*, 54(5):637–651, 2021.

[25] Mark Hudson, A Chitolie, RA Hutton, MS Smith, RE Pounder, and AJ Wakefield. Thrombotic vascular risk factors in inflammatory bowel disease. *Gut*, 38(5):733, 1996.

[26] Tine Jess, Britt W Jensen, Mikael Andersson, Marie Villumsen, and Kristine H Allin. Inflammatory bowel diseases increase risk of type 2 diabetes in a nationwide cohort study. *Clin. Gastroenterol. Hepatol.*, 18(4):881–888, 2020.

[27] Steven R Ytterberg, Deepak L Bhatt, Ted R Mikuls, Gary G Koch, Roy Fleischmann, Jose L Rivas, Rebecca Germino, Sujatha Menon, Yanhui Sun, Cunshan Wang, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. *N. Engl. J. Med.*, 386(4):316–326, 2022.

[28] Tania H Bisgaard, Kristine H Allin, Rahma Elmahdi, and Tine Jess. The bidirectional risk of inflammatory bowel disease and anxiety or depression: A systematic review and meta-analysis. *Gen. Hosp. Psychiatry*, 83:109–116, 2023.

[29] Yohei Mikami, Junya Tsunoda, Hiroki Kiyohara, Nobuhito Taniki, Toshiaki Teratani, and Takanori Kanai. Vagus nerve-mediated intestinal immune regulation: therapeutic implications of inflammatory bowel diseases. *Int. Immunol.*, 34(2):97–106, 2022.

[30] Eva M Szigethy, John I Allen, Marci Reiss, Wendy Cohen, Lilani P Perera, Lili Brillstein, Raymond K Cross, David A Schwartz, Lawrence R Kosinski, Joshua B Colton, et al. White paper AGA: the impact of mental and psychosocial factors on the care of patients with inflammatory bowel disease. *Clin. Gastroenterol. Hepatol.*, 15(7): 986–997, 2017.

[31] Beatriz Gros, Jonathan Blackwell, Jonathan Segal, Christopher J Black, Alexander C Ford, and Shahida Din. Harms with placebo in trials of biological therapies and small molecules as maintenance therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.*, 9(11):1030–1040, 2024.

[32] Shahida Din, Jonathan Segal, Jonathan Blackwell, Beatriz Gros, Christopher J Black, and Alexander C Ford. Harms with placebo in trials of biological therapies and small molecules as induction therapy in inflammatory bowel disease: a systematic review and meta-analysis. *Lancet Gastroenterol. Hepatol.*, 9(11):1020–1029, 2024.

[33] Kristen L Farraj, James R Pellegrini, Rezwan F Munshi, Jose Russe-Russe, Aboud Kaliounji, Muhammad S Tiwana, Pranay Srivastava, and Krishnayer Subramani. Chronic steroid use: An overlooked impact on patients with inflammatory bowel disease. *JGH Open*, 6(12):910–914, 2022.

Keywords

inflammatory bowel disease; Crohn's disease, ulcerative colitis, pre-diagnosis, comorbid diseases

Author contributions:

ACE, GP, MB, and TJ conceptualised the paper and RE contributed key analysis concepts. All authors were involved in the developing the methodology, and validation of findings. ACE and GP developed the code for and undertook the analysis. ACE, GP, and MB provided the formal statistical methodology input. AS and ACE developed the Finnish validation analysis. The original draft was written by RE, ACE, MB, CWL, and TJ. All authors contributed to review and editing of the manuscript. ACE, RE, MB, BV, CWL, AS and TJ contributed to the visualisation of findings.

Funding

This study was supported by grants from the Danish National Research Foundation (DNRF148) and the Novo Nordisk Foundation (NNF21OC0068631) to TJ. CWL is funded by a UKRI (UK research and Innovation) Future Leaders Fellowship "Predicting outcomes in IBD" (MR/S034919/1). BV is supported by the Clinical Research Fund (KOOR) at the University Hospitals Leuven and the Research Council at the KU Leuven.

Conflicts of interest

ACE, GP, MB and RE report no competing interests. BV reports research support from AbbVie, Biora Therapeutics, Landos, Pfizer, Sossei Heptares and Takeda; speaker fees from Abbvie, Biogen, Bristol Myers Squibb, Celltrion, Chiesi, Falk, Ferring, Galapagos, Janssen, MSD, Pfizer, R-Biopharm, Takeda, Truvion and Viatris; consultancy fees from Abbvie, Alimentiv, Applied Strategic, Atheneum, Biora Therapeutics, Bristol Myers Squibb, Galapagos, Guidepont, Landos, Mylan, Inotrem, Ipsos, Janssen, Pfizer, Progenity, Sandoz, Sosei Heptares, Takeda, Tillots Pharma and Viatris. CWL has acted as a consultant to Abbvie, Janssen, Takeda, Pfizer, Galapagos, Bristol Myers Squibb, B.I., Sandoz, Novartis, GSK, Gilead, ViforPharma, Dr Falk, Trellus Health and Iterative Scopes; he has received speaking fees and travel support from Pfizer, Janssen, Abbvie, Galapagos, MSD, Takeda, Shire, Ferring, Hospira and Dr Falk. TJ reports consultancy fee from Ferring Pharmaceuticals and Pfizer.

Acknowledgements

We wish to thank Carsten Eriksen for his assistance with improving the readability of the forest plots.

Data sharing

The study was based on data from the Danish National Health registers (https://sundhedsdatastyrelsen.dk). The register data are protected by the Danish Act on Processing of Personal Data and are accessed through application to and approval from the Danish Data Protection Agency and the Danish Health Data Authority.

5 Tables and figures

Table 1: Demographic baseline characteristics (age (years), year of diagnosis, sex at birth) of inflammatory bowel disease patients (Crohn's disease and ulcerative colitis) and sex- and age- match controls.

	Crohn's disease		Ulcerative colitis	
	N = 11,298	controls, N = 67,788	N = 23,067	controls, N = 138,402
Age of IBD onset (index date), y				
17-39	5,749 (50.9%)	34,458 (50.8%)	9,306 (40.3%)	55,817 (40.3%)
40-59	3,144 (27.8%)	18,934 (27.9%)	7,401 (32.1%)	44,375 (32.1%)
60+	2,405 (21.3%)	14,396 (21.2%)	6,360 (27.6%)	38,210 (27.6%)
Calendar year of birth				
1905-1939	740 (6.5%)	4,440 (6.5%)	2,501 (10.8%)	15,006 (10.8%)
1940-1959	2,508 (22.2%)	15,048 (22.2%)	6,230 (27.0%)	37,380 (27.0%)
1960-1979	3,506 (31.0%)	21,036 (31.0%)	7,740 (33.6%)	46,440 (33.6%)
1980-2003	4,544 (40.2%)	27,264 (40.2%)	6,596 (28.6%)	39,576 (28.6%)
Calendar year of IBD diagnosis (index date)				
2005-2009	2,724 (24.1%)	16,344 (24.1%)	6,977 (30.2%)	41,862 (30.2%)
2010-2014	3,261 (28.9%)	19,566 (28.9%)	7,265 (31.5%)	43,590 (31.5%)
2015-2018	3,134 (27.7%)	18,804 (27.7%)	5,494 (23.8%)	32,964 (23.8%)
2019-2021	2,179 (19.3%)	13,074 (19.3%)	3,331 (14.4%)	19,986 (14.4%)
Sex				
Female	6,368 (56.4%)	38,208 (56.4%)	11,916 (51.7%)	71,496 (51.7%)
Male	4,930 (43.6%)	29,580 (43.6%)	11,151 (48.3%)	66,906 (48.3%)



Figure 1: Cumulative incidence of three-character level diagnosis presented by ICD-10 chapter for CD, Crohn's disease and UC, ulcerative colitis and age-, sex-, and municipality-matched controls from -10 years to 10 years from IBD, inflammatory bowel disease diagnosis.

	prediag. OR(95% CI)	prediag. events	postdiag. HR(95%CI)	postdiag. events
Infectious and parasitic diseases (I)				
A08 Viral and other specified intestinal infections (+FI)	2.23 (1.58, 3.10)	50/ 22.5	4.65 (3.24, 6.66)	52/ 11.5
A46 Erysipelas (+FI)	1.49 (1.17, 1.89)	89/ 59.8	2.03 (1.75, 2.36)	226/ 115.2
A49 Bacterial infection of unspecified site (+FI)	2.14 (1.62, 2.82)	73/ 34.2	2.40 (2.09, 2.75)	285/ 123.5
A60 Anogenital herpesviral [herpes simplex] infection	1.61 (0.84, 2.88)	15/ 9.3	3.41 (2.09, 5.55)	25/ 7.5
B00 Herpesviral [herpes simplex] infections	1.76 (0.96, 3.07)	17/ 9.7	4.04 (2.76, 5.91)	44/ 11.2
B02 Zoster [herpes zoster] (+FI)	1.85 (0.98, 3.29)	16/ 8.7	2.33 (1.67, 3.26)	47/ 20.7
B07 Viral warts (+FI)	0.88 (0.41, 1.72)	10/ 11.3	4.99 (3.08, 8.07)	30/ 6.2
B25 Cytomegalovirus (+FI)	1.77 (0.51, 4.98)	5/ 2.8	13.00 (7.20,23.60)	34/ 2.7
B34 Viral infection of unspecified site	1.53 (1.19, 1.94)	87/ 57.2	1.65 (1.41, 1.93)	196/ 122.5
B35 Dermatophytosis	1.24 (0.46, 2.83)	7/ 5.7	3.07 (1.88, 5.02)	24/ 8.0
B37 Candidiasis	1.63 (1.03, 2.50)	28/ 17.2	2.93 (2.34, 3.67)	111/ 39.0
Neoplasms (II)				
C17 Malignant neoplasm of small intestine (+FI)	0.00 (0.00, 5.10)	0/ 1.0	7.45 (4.48,12.40)	33/ 4.5
C34 Malignant neoplasm of bronchus and lung	1.26 (0.69, 2.19)	16/ 12.7	1.68 (1.38, 2.06)	121/ 73.8
C83 Non−follicular lymphoma	1.38 (0.71, 2.49)	14/ 10.2	2.50 (1.69, 3.71)	35/ 14.3
D12 Benign neoplasm of colon, rectum, anus and anal canal (+FI)	1.85 (1.59, 2.14)	240/ 131.0	1.19 (1.06, 1.33)	334/ 297.7
D13 Benign neoplasm of other and ill−defined parts of gut (+FI)	2.29 (1.37, 3.72)	24/ 10.5	2.75 (1.94, 3.90)	46/ 17.2
D22 Melanocytic naevi	1.13 (0.87, 1.47)	71/ 62.7	1.74 (1.45, 2.09)	146/ 86.3
D35 Benign neoplasm of other and unspecified endocrine glands	2.27 (1.42, 3.56)	28/ 12.3	2.55 (1.85, 3.51)	53/ 21.3
Blood and certain immune mechanisms (III)				
D50 Iron deficiency anaemia (+FI)	4.16 (3.35, 5.16)	147/ 35.7	3.04 (2.59, 3.56)	225/ 78.3
D51 Vitamin B 12 deficiency anaemia (+FI)	2.93 (1.65, 5.06)	21/ 7.2	3.76 (2.29, 6.18)	25/ 6.8
D62 Acute posthaemorrhagic anaemia (+FI)	2.17 (1.33, 3.44)	26/ 12.0	2.64 (1.94, 3.60)	58/ 22.5
D69 Purpura and other haemorrhagic conditions	1.39 (0.90, 2.10)	29/ 20.8	2.17 (1.56, 3.02)	48/ 22.7
Endocrine, nutritional and metabolic (IV)				
E10 Type 1 diabetes mellitus	1.19 (0.98, 1.45)	131/ 109.8	1.81 (1.44, 2.26)	98/ 55.5
E11 Type 2 diabetes mellitus	1.34 (1.17, 1.54)	265/ 198.8	1.37 (1.20, 1.57)	253/ 191.0
E41 Nutritional marasmus			3.13 (1.99, 4.94)	28/ 9.2
E53 Deficiency of other B group vitamins	1.33 (0.45, 3.30)	6/ 4.5	3.08 (2.08, 4.57)	37/ 12.3
E55 Vitamin D deficiency	1.93 (1.28, 2.85)	35/ 18.2	2.52 (1.93, 3.29)	76/ 31.0
E61 Deficiency other nutrients	1.67 (0.48, 4.66)	5/ 3.0	9.33 (5.74,15.20)	41/ 4.5
E64 Sequelae of other nutritional deficiencies	3.64 (2.07, 6.27)	23/ 6.3	8.64 (6.51,11.50)	115/ 13.7
E66 Obesity	1.36 (1.23, 1.50)	546/ 406.8	1.46 (1.34, 1.60)	611/ 439.8
E73 Lactose intolerance	3.87 (2.51, 5.93)	38/ 9.8	8.27 (5.83,11.70)	74/ 9.2
E78 Disorders of lipoprotein metabolism and other lipidaemias (+FI)	1.37 (1.21, 1.56)	308/ 226.3	1.15 (1.01, 1.30)	287/ 258.3
E83 Disorders of mineral metabolism	1.17 (0.62, 2.05)	15/ 12.8	2.77 (2.18, 3.52)	97/ 36.0
E86 Volume depletion (+FI)	2.03 (1.60, 2.56)	100/ 49.5	2.82 (2.53, 3.15)	458/ 170.5
Mental and behavioural disorders (V)				
F05 Delirium, not induced by alcohol and other psychoactives	1.24 (0.42, 3.04)	6/ 4.8	1.83 (1.41, 2.38)	74/ 41.5
F10 Mental and behavioural disorders due to use of alcohol	1.10 (0.96, 1.27)	242/ 219.8	1.54 (1.30, 1.81)	174/ 116.7
F11 Mental and behavioural disorders due to use of opioids	1.54 (0.69, 3.14)	10/ 6.5	3.13 (2.00, 4.89)	29/ 9.5
F17 Mental and behavioural disorders due to use of tobacco	2.36 (2.00, 2.78)	207/ 88.7	4.04 (3.51, 4.65)	322/ 84.8
F32 Depressive episode (+FI)	1.66 (1.31, 2.10)	94/ 56.7	1.68 (1.42, 2.00)	165/ 101.2
F33 Recurrent depressive disorder (+FI)	1.84 (1.39, 2.40)	73/ 39.8	1.92 (1.63, 2.26)	191/ 102.8
F34 Persistent mood [affective] disorders	1.64 (0.69, 3.50)	9/ 5.5	3.89 (2.38, 6.36)	26/ 6.8
F43 Reaction to severe stress, and adjustment disorders (+FI)	1.17 (0.89, 1.51)	72/ 61.7	1.62 (1.40, 1.87)	227/ 144.3
F60 Specific personality disorders	2.58 (1.72, 3.79)	39/ 15.2	1.81 (1.45, 2.27)	100/ 56.7
Nervous system (VI)				
G43 Migraine (+FI)	1.67 (1.39, 1.99)	162/ 97.5	1.96 (1.64, 2.34)	160/ 84.7
G47 Sleep disorders	1.58 (1.33, 1.87)	174/ 110.8	1.41 (1.24, 1.62)	262/ 191.3
Eye and adnexa (VII)				
H10 Conjunctivitis	1.45 (1.20, 1.75)	145/ 100.2	1.99 (1.64, 2.42)	136/ 70.7
H15 Disorders of sclera (+FI)	2.73 (1.15, 6.01)	10/ 3.7	7.43 (4.05,13.60)	23/ 3.2
H16 Keratitis	1.19 (0.81, 1.70)	37/ 31.2	1.93 (1.46, 2.55)	65/ 34.5
H20 Iridocyclitis (+FI)	2.29 (1.68, 3.09)	62/ 27.2	3.26 (2.36, 4.49)	57/ 18.0
H53 Visual disturbances	1.54 (1.17, 2.01)	71/ 46.2	1.74 (1.39, 2.18)	98/ 57.8
Circulatory system (IX)				
I10 Essential (primary) hypertension	1.46 (1.35, 1.59)	812/ 567.5	1.17 (1.08, 1.27)	670/ 608.5
I25 Chronic ischaemic heart disease (+FI)	1.29 (1.12, 1.49)	235/ 182.7	1.45 (1.25, 1.67)	229/ 163.2
I26 Pulmonary embolism	1.02 (0.68, 1.48)	33/ 32.5	2.01 (1.66, 2.43)	139/ 71.3
I50 Heart failure	1.50 (1.22, 1.83)	125/ 83.5	1.51 (1.31, 1.75)	224/ 152.7
I70 Atherosclerosis	1.91 (1.50, 2.42)	95/ 49.8	1.78 (1.42, 2.23)	98/ 56.7
I74 Arterial embolism and thrombosis	2.16 (1.19, 3.77)	18/ 8.3	2.93 (1.91, 4.50)	31/ 10.8
I80 Phlebitis and thrombophlebitis	1.54 (1.24, 1.90)	115/ 74.8	1.90 (1.61, 2.24)	185/ 100.5
Respiratory system (X)				
J01 Acute sinusitis (+FI)	1.62 (1.10, 2.32)	39/ 24.2	2.42 (1.89, 3.10)	88/ 37.3
J03 Acute tonsillitis (+FI)	1.47 (1.22, 1.75)	158/ 108.2	1.72 (1.45, 2.04)	165/ 99.0
J06 Acute upper resp. infections of multiple & unspecified sites (+FI)	1.43 (0.97, 2.07)	36/ 25.2	1.88 (1.50, 2.35)	99/ 54.2
J09 Influenza due to identified zoonotic or pandemic influenza virus	1.29 (0.44, 3.17)	6/ 4.7	2.36 (1.63, 3.44)	38/ 16.5
J18 Pneumonia, organism unspecified (+FI)	1.49 (1.31, 1.70)	293/ 198.2	1.89 (1.74, 2.06)	693/ 386.3
J22 Unspecified acute lower respiratory infection	1.25 (0.56, 2.50)	10/ 8.0	3.11 (2.10, 4.59)	38/ 12.5
J35 Chronic diseases of tonsils and adenoids	1.62 (1.40, 1.88)	235/ 146.2	1.61 (1.30, 1.99)	105/ 67.5
J37 Chronic laryngitis and laryngotracheitis	1.50 (0.72, 2.87)	12/ 8.0	4.10 (2.26, 7.45)	18/ 4.5
J43 Emphysema	1.60 (0.77, 3.08)	12/ 7.5	2.28 (1.63, 3.19)	47/ 21.2
J45 Asthma (+FI)	1.82 (1.62, 2.03)	411/ 230.2	1.79 (1.57, 2.03)	297/ 175.2
J47 Bronchiectasis	2.27 (1.28, 3.86)	20/ 8.8	2.50 (1.76, 3.57)	43/ 17.7
Digestive system (XI)				
K02 Dental caries (+FI)	1.25 (0.80, 1.90)	28/ 22.3	2.47 (1.77, 3.44)	49/ 20.3
K12 Stomatitis and related lesions (+FI)	2.52 (1.69, 3.70)	39/ 15.5	2.79 (2.02, 3.87)	53/ 19.5
K20 Oesophagitis	2.00 (1.40, 2.82)	46/ 23.0	2.49 (1.90, 3.25)	74/ 30.7
K21 Gastro−oesophageal reflux disease (+FI)	2.29 (1.98, 2.64)	277/ 122.7	1.78 (1.54, 2.06)	239/ 141.2
K25 Gastric ulcer (+FI)	2.58 (2.04, 3.24)	108/ 42.2	1.71 (1.36, 2.16)	90/ 54.5
K26 Duodenal ulcer	3.40 (2.47, 4.64)	66/ 19.5	2.49 (1.84, 3.38)	58/ 24.0
K29 Gastritis and duodenitis (+FI)	2.93 (2.53, 3.38)	288/ 100.0	2.51 (2.15, 2.93)	226/ 95.3
K30 Functional dyspepsia (+FI)	2.36 (2.04, 2.72)	272/ 116.8	2.02 (1.71, 2.39)	183/ 95.5
K35 Acute appendicitis (+FI)	1.60 (1.37, 1.85)	222/ 140.2	1.59 (1.33, 1.91)	144/ 95.2
K43 Ventral hernia (+FI)	2.42 (1.89, 3.07)	99/ 41.2	6.89 (5.91, 8.04)	341/ 51.8
K44 Diaphragmatic hernia (+FI)	2.67 (2.25, 3.17)	200/ 75.7	1.69 (1.41, 2.02)	153/ 94.8
K46 Unspecified abdominal hernia	3.89 (1.64, 8.80)	11/ 2.8	4.16 (2.39, 7.23)	21/ 5.2
K55 Vascular disorders of intestine (+FI)	4.92 (2.48, 9.60)	18/ 3.7	5.57 (4.16, 7.46)	86/ 15.8
K56 Paralytic ileus and obstruction of gut without hernia (+FI)	4.99 (3.96, 6.28)	140/ 28.3	12.60 (11.10,14.30)	677/ 59.0
K57 Diverticular disease of intestine (+FI)	2.83 (2.46, 3.24)	314/ 113.2	1.55 (1.37, 1.74)	331/ 229.0
K58 Irritable bowel syndrome (+FI)	3.72 (3.24, 4.28)	340/ 93.3	5.29 (4.64, 6.04)	404/ 83.3
K60 Fissure and fistula of anal and rectal regions (+FI)	6.43 (5.48, 7.54)	325/ 51.8	10.10 (8.85,11.60)	535/ 58.7
K61 Abscess of anal and rectal regions (+FI)	8.36 (7.03, 9.95)	318/ 39.0	9.12 (7.68,10.80)	311/ 37.2
K64 Haemorrhoids and perianal venous thrombosis	2.59 (2.28, 2.94)	360/ 141.8	1.81 (1.60, 2.04)	336/ 198.8
K65 Peritonitis (+FI)	3.81 (2.66, 5.40)	55/ 14.5	11.70 (9.40,14.60)	225/ 20.0
K71 Toxic liver disease	1.78 (0.70, 4.03)	8/ 4.5	4.98 (3.08, 8.06)	30/ 6.2
K74 Fibrosis and cirrhosis of liver (+FI)	2.60 (1.25, 5.14)	13/ 5.0	2.92 (2.08, 4.11)	49/ 17.2
K80 Cholelithiasis (+FI)	1.85 (1.64, 2.08)	379/ 208.3	1.79 (1.60, 2.01)	371/ 219.7
K81 Cholecystitis	1.78 (1.26, 2.47)	48/ 27.0	1.87 (1.46, 2.41)	79/ 43.5
K85 Acute pancreatitis (+FI)	1.83 (1.30, 2.54)	49/ 26.8	5.17 (4.31, 6.21)	211/ 42.2
K90 Intestinal malabsorption (+FI)	4.73 (3.45, 6.45)	76/ 16.2	7.17 (5.51, 9.34)	119/ 17.2



prediagnostic — postdiagnostic

Figure 2a: Crohn's disease associated diagnoses at the ICD-10 three-character level, first part (Chapters I-XI). Pre-diagnostic OR, odds ratio and 95% CI, confidence intervals and post-diagnostic HR, hazard ratio and 95% CI estimates compared with age-, sex- and municipality-matched controls. Diagnoses meeting the prevalence threshold ($\geq 0.2\%$) with disease-wide significance (Bonferroni correction: $p < 7.90 \times 10^{-6}$) are included. The "(+FI)" symbol indicates that this effect is also significant in the Finnish registry.

	prediag. OR(95% CI)	prediag. events	postdiag. HR(95%CI)	postdiag. events
Skin and subcutaneous tissue (XII)				
L02 Cutaneous abscess, furuncle and carbuncle (+FI)	1.97 (1.69, 2.28)	247/ 127.0	2.65 (2.34, 3.01)	336/ 133.3
L03 Cellulitis	1.24 (0.93, 1.63)	63/ 50.8	2.17 (1.65, 2.86)	68/ 32.2
L05 Pilonidal cyst	1.72 (1.34, 2.19)	89/ 51.8	2.51 (1.93, 3.26)	79/ 32.3
L20 Atopic dermatitis (+FI)	1.63 (1.17, 2.25)	50/ 30.7	2.67 (1.94, 3.69)	53/ 20.3
L21 Seborrhoeic dermatitis (+FI)	1.53 (0.74, 2.94)	12/ 7.8	9.43 (6.62,13.40)	78/ 8.5
L27 Dermatitis due to substances taken internally			4.37 (2.62, 7.30)	25/ 5.8
L29 Pruritus	1.64 (0.95, 2.73)	20/ 12.2	2.71 (1.98, 3.71)	56/ 21.2
L40 Psoriasis (+FI)	2.58 (2.00, 3.31)	93/ 36.2	5.67 (4.70, 6.85)	208/ 38.0
L50 Urticaria (+FI)	1.73 (1.36, 2.17)	96/ 55.8	2.34 (1.90, 2.88)	122/ 53.8
L52 Erythema nodosum (+FI)	2.91 (1.46, 5.55)	15/ 5.2	9.97 (5.79,17.20)	34/ 3.5
L57 Skin changes due to chronic exposure to nonionizing radiation (+FI)	1.11 (0.66, 1.77)	21/ 19.0	2.02 (1.51, 2.70)	60/ 30.5
L63 Alopecia areata	4.00 (1.76, 8.79)	12/ 3.0	6.86 (3.57,13.20)	19/ 2.8
L70 Acne (+FI)	1.45 (0.84, 2.38)	20/ 13.8	6.71 (4.74, 9.49)	67/ 10.2
L71 Rosacea (+FI)	1.83 (1.02, 3.15)	18/ 9.8	5.16 (3.88, 6.86)	87/ 17.3
L88 Pyoderma gangrenosum (+FI)			29.40 (11.20,77.10)	24/ 0.8
L90 Atrophic disorders of skin	1.40 (1.10, 1.76)	92/ 66.0	2.28 (1.89, 2.76)	147/ 66.5
Musculoskeletal and connective (XIII)				
M02 Reactive arthropathies (+FI)	2.07 (1.42, 2.96)	42/ 20.3	2.91 (2.01, 4.19)	42/ 14.8
M06 Rheumatoid arthritis	2.18 (1.69, 2.80)	87/ 40.0	2.22 (1.70, 2.90)	73/ 33.8
M07 Psoriatic and enteropathic arthropathies (+FI)	3.59 (2.66, 4.82)	75/ 21.0	19.10 (15.60,23.50)	367/ 20.2
M08 Juvenile arthritis	3.18 (2.06, 4.84)	36/ 11.3	5.37 (1.95,14.80)	7/ 1.3
M22 Disorders of patella	1.55 (1.34, 1.79)	235/ 152.7	0.81 (0.59, 1.12)	42/ 53.3
M23 Internal derangement of knee	1.23 (1.13, 1.34)	632/ 518.8	1.08 (0.97, 1.21)	371/ 355.2
M45 Ankylosing spondylitis (+FI)	10.80 (7.75,15.10)	105/ 9.8	11.30 (7.80,16.30)	80/ 7.3
M47 Spondylosis	1.97 (1.64, 2.35)	165/ 84.5	1.45 (1.23, 1.70)	183/ 131.2
M50 Cervical disc disorders (+FI)	1.82 (1.46, 2.26)	111/ 61.3	1.32 (1.07, 1.63)	107/ 83.5
M54 Dorsalgia (+FI)	1.65 (1.51, 1.81)	636/ 393.3	1.60 (1.47, 1.74)	680/ 454.3
M65 Synovitis and tenosynovitis	1.51 (1.30, 1.74)	241/ 161.0	1.27 (1.10, 1.47)	213/ 173.2
M75 Shoulder lesions (+FI)	1.36 (1.23, 1.51)	459/ 340.0	1.26 (1.14, 1.39)	473/ 390.7
M80 Osteoporosis with pathological fracture (+FI)	2.02 (1.45, 2.76)	54/ 26.8	2.17 (1.79, 2.63)	140/ 66.5
M81 Osteoporosis without pathological fracture (+FI)	1.79 (1.51, 2.11)	190/ 107.0	2.56 (2.30, 2.86)	450/ 183.8
M86 Osteomyelitis	2.77 (1.49, 4.96)	18/ 6.5	3.20 (2.01, 5.09)	27/ 8.7
Genitourinary system (XIV)				
N10 Acute tubulo−interstitial nephritis (+FI)	1.62 (1.22, 2.12)	69/ 42.7	2.61 (2.04, 3.34)	90/ 35.5
N13 Obstructive and reflux uropathy	1.11 (0.75, 1.59)	35/ 31.7	2.63 (2.12, 3.27)	116/ 45.3
N17 Acute renal failure (+FI)	1.45 (0.85, 2.36)	21/ 14.5	2.19 (1.78, 2.70)	120/ 56.3
N18 Chronic kidney disease (+FI)	1.59 (1.14, 2.18)	50/ 31.5	2.35 (1.98, 2.78)	185/ 81.2
N19 Unspecified kidney failure (+FI)	1.08 (0.55, 1.97)	13/ 12.0	2.53 (1.91, 3.35)	69/ 28.0
N20 Calculus of kidney and ureter (+FI)	1.43 (1.19, 1.70)	154/ 108.5	2.36 (2.04, 2.72)	258/ 113.7
N30 Cystitis (+FI)	1.64 (1.45, 1.84)	359/ 222.2	1.67 (1.51, 1.83)	518/ 328.5
N75 Diseases of Bartholin gland	1.81 (1.17, 2.73)	31/ 17.2	2.28 (1.61, 3.22)	44/ 19.8
N82 Fistulae of female genital tract (+FI)	4.75 (2.24, 9.86)	15/ 3.2	15.00 (8.38,26.80)	39/ 2.7
N83 Noninfl. dis. ovary, fallopian tube, broad ligament (+FI)	1.70 (1.43, 2.02)	177/ 105.3	1.92 (1.64, 2.25)	200/ 109.2
N87 Dysplasia of cervix uteri	1.26 (1.00, 1.57)	98/ 78.0	1.66 (1.37, 2.00)	137/ 85.0
N94 Pain & other cond. of fem. genital organs & menstrual cycle (+FI)	1.66 (1.35, 2.02)	132/ 80.3	1.84 (1.51, 2.25)	124/ 69.5
N97 Female infertility	1.07 (0.88, 1.29)	136/ 127.3	1.47 (1.26, 1.72)	192/ 133.8
Pregnancy, childbirth and the puerperium (XV)				
O26 Maternal care for conditions predominantly related to pregnancy	1.28 (1.06, 1.53)	149/ 117.3	1.61 (1.33, 1.95)	131/ 83.8
O82 Single delivery by caesarean section	1.05 (0.92, 1.20)	262/ 249.3	1.67 (1.48, 1.88)	353/ 219.8
Congenital diseases (XVII)				
Q61 Cystic kidney disease	1.10 (0.60, 1.90)	16/ 14.5	2.91 (2.08, 4.07)	50/ 17.7
Symptoms, signs and findings (XVIII)				
R00 Abnormalities of heart beat	1.72 (1.40, 2.10)	128/ 74.8	1.45 (1.24, 1.69)	196/ 140.0
R05 Cough (+FI)	1.56 (1.29, 1.88)	146/ 93.8	1.66 (1.42, 1.94)	197/ 122.7
R06 Abnormalities of breathing (+FI)	1.52 (1.34, 1.72)	324/ 215.7	1.69 (1.55, 1.85)	649/ 401.7
R07 Pain in throat and chest (+FI)	1.48 (1.30, 1.68)	303/ 206.3	1.65 (1.51, 1.81)	590/ 373.8
R10 Abdominal and pelvic pain (+FI)	2.45 (2.31, 2.59)	1854/ 838.5	3.04 (2.88, 3.22)	1654/ 824.5
R11 Nausea and vomiting (+FI)	1.92 (1.50, 2.44)	91/ 47.7	2.93 (2.60, 3.32)	373/ 132.7
R13 Dysphagia (+FI)	1.40 (0.99, 1.94)	46/ 32.8	2.00 (1.68, 2.39)	166/ 85.5
R15 Faecal incontinence (+FI)	2.50 (1.75, 3.52)	49/ 19.7	2.44 (1.81, 3.28)	60/ 25.3
R20 Disturbances of skin sensation (+FI)	1.39 (0.89, 2.11)	28/ 20.2	2.07 (1.63, 2.64)	89/ 44.2
R21 Rash and other nonspecific skin eruption (+FI)	2.00 (1.23, 3.16)	26/ 13.0	4.42 (3.47, 5.62)	113/ 26.3
R30 Pain associated with micturition	1.38 (0.71, 2.49)	14/ 10.2	2.79 (1.98, 3.92)	48/ 17.7
R31 Unspecified haematuria (+FI)	1.69 (1.45, 1.97)	222/ 132.2	1.67 (1.45, 1.93)	235/ 146.2
R33 Retention of urine	1.42 (1.11, 1.80)	87/ 61.5	1.59 (1.35, 1.88)	177/ 114.5
R42 Dizziness and giddiness (+FI)	1.44 (1.19, 1.73)	145/ 101.0	1.42 (1.24, 1.63)	255/ 185.3
R49 Voice disturbances	1.15 (0.78, 1.65)	36/ 31.3	2.54 (1.93, 3.34)	72/ 29.2
R50 Fever of other and unknown origin (+FI)	1.83 (1.49, 2.23)	129/ 71.0	3.24 (2.88, 3.66)	405/ 132.0
R51 Headache (+FI)	1.55 (1.32, 1.81)	202/ 131.2	1.95 (1.72, 2.21)	318/ 170.0
R53 Malaise and fatigue (+FI)	1.64 (1.34, 1.98)	137/ 84.2	1.95 (1.75, 2.18)	426/ 227.2
R55 Syncope and collapse	1.43 (1.27, 1.62)	334/ 235.3	1.21 (1.06, 1.37)	270/ 231.7
R59 Enlarged lymph nodes	2.31 (1.68, 3.13)	59/ 25.7	2.14 (1.55, 2.97)	49/ 23.5
R63 Symptoms and signs concerning food and fluid intake	2.91 (2.10, 4.00)	60/ 20.7	2.12 (1.78, 2.52)	172/ 84.7
R74 Abnormal serum enzyme levels (+FI)	1.98 (1.26, 3.02)	30/ 15.2	2.80 (2.16, 3.62)	84/ 30.8
R91 Abnormal findings on diagnostic imaging of lung (+FI)	2.11 (1.66, 2.65)	102/ 48.7	2.10 (1.83, 2.42)	268/ 132.2
R93 Abnormal findings on diagnostic imaging of other body structures	1.76 (1.29, 2.37)	58/ 33.0	1.79 (1.43, 2.23)	100/ 57.7
Injury, poisoning, other external causes (XIX)				
S13 Disloc., sprain & strain of joints & ligaments at neck level	1.54 (1.35, 1.74)	320/ 210.2	1.30 (1.09, 1.55)	146/ 116.5
S20 Superficial injury of thorax	1.40 (1.23, 1.59)	315/ 226.7	1.37 (1.16, 1.61)	178/ 134.5
S30 Superficial injury of abdomen, lower back and pelvis	1.50 (1.32, 1.72)	286/ 191.7	1.23 (1.02, 1.48)	129/ 108.5
S31 Open wound of abdomen, lower back and pelvis	1.00 (0.60, 1.60)	21/ 21.0	2.97 (1.95, 4.53)	32/ 11.0
S50 Superficial injury of forearm	1.38 (1.25, 1.53)	491/ 360.0	1.27 (1.08, 1.51)	161/ 130.8
S60 Superficial injury of wrist and hand	1.32 (1.23, 1.41)	1142/ 888.2	1.30 (1.17, 1.45)	407/ 330.5
S62 Fracture at wrist and hand level	1.17 (1.07, 1.27)	635/ 548.5	1.31 (1.16, 1.47)	344/ 272.8
S63 Disloc., sprain & strain of joints & ligaments at wrist and hand	1.23 (1.13, 1.34)	713/ 586.0	1.16 (1.01, 1.33)	252/ 225.7
S70 Superficial injury of hip and thigh	1.17 (1.00, 1.37)	194/ 166.2	1.58 (1.34, 1.87)	174/ 113.0
S80 Superficial injury of lower leg	1.35 (1.24, 1.47)	678/ 510.7	1.36 (1.19, 1.55)	269/ 207.2
S83 Disloc., sprain & strain of joints & ligaments of knee	1.24 (1.14, 1.34)	769/ 630.3	0.89 (0.78, 1.02)	254/ 293.3
S90 Superficial injury of ankle and foot	1.32 (1.22, 1.43)	796/ 613.3	1.33 (1.18, 1.51)	303/ 238.2
S93 Disloc., sprain & strain of joints & ligaments at ankle and foot	1.22 (1.14, 1.30)	1263/1060.2	1.15 (1.04, 1.28)	410/ 373.5
T83 Complications of genitourinary devices, implants and grafts	1.16 (0.63, 1.99)	16/ 13.8	1.99 (1.51, 2.62)	68/ 35.0



Figure 2b: Crohn's disease associated diagnoses at the ICD-10 three-character level, first part (Chapters XI-XIX). Pre-diagnostic OR, odds ratio and 95% CI, confidence intervals and post-diagnostic HR, hazard ratio and 95% CI estimates compared with age-, sex- and municipality-matched controls. Diagnoses meeting the prevalence threshold ($\geq 0.2\%$) with disease-wide significance (Bonferroni correction: $p < 7.90 \times 10^{-6}$) are included. The "(+FI)" symbol indicates that this effect is also significant in the Finnish registry.

	prediag. OR(95% CI)	prediag. events	postdiag. HR(95%CI)	postdiag. events
Infectious and parasitic diseases (I)				
A08 Viral and other specified intestinal infections (+FI)	1.64 (1.24, 2.15)	69/ 42.2	3.18 (2.48, 4.09)	94/ 30.0
A46 Erysipelas (+FI)	1.31 (1.10, 1.54)	169/ 129.7	1.40 (1.25, 1.57)	371/ 269.0
A49 Bacterial infection of unspecified site (+FI)	1.30 (1.03, 1.63)	93/ 71.5	1.70 (1.55, 1.86)	584/ 351.3
B02 Zoster [herpes zoster] (+FI)	1.36 (0.89, 2.02)	31/ 22.8	2.02 (1.61, 2.55)	95/ 47.7
B23 Human immunodeficiency virus related conditions	1.60 (1.02, 2.45)	28/ 17.5	3.92 (2.23, 6.87)	20/ 5.2
B25 Cytomegalovirus (+FI)	2.93 (1.65, 5.05)	21/ 7.2	11.50 (7.61,17.30)	66/ 5.8
B34 Viral infection of unspecified site	1.11 (0.89, 1.36)	110/ 99.5	1.55 (1.38, 1.74)	354/ 233.3
B37 Candidiasis	1.08 (0.77, 1.49)	46/ 42.5	2.19 (1.86, 2.58)	193/ 89.8
Neoplasms (II)				
C61 Malignant neoplasm of prostate	1.60 (1.34, 1.90)	171/ 107.3	0.88 (0.76, 1.04)	175/ 199.7
D12 Benign neoplasm of colon, rectum, anus and anal canal (+FI)	2.14 (1.95, 2.35)	633/ 300.2	1.19 (1.11, 1.28)	921/ 821.5
D13 Benign neoplasm of other and ill−defined parts of gut (+FI)	1.63 (1.14, 2.29)	44/ 27.0	1.79 (1.41, 2.27)	88/ 50.0
D22 Melanocytic naevi	1.14 (0.94, 1.38)	131/ 114.8	1.55 (1.35, 1.77)	268/ 176.2
Blood and certain immune mechanisms (III)				
D50 Iron deficiency anaemia (+FI)	1.33 (1.07, 1.64)	106/ 79.8	2.07 (1.84, 2.31)	398/ 197.3
D62 Acute posthaemorrhagic anaemia (+FI)	1.19 (0.82, 1.68)	39/ 32.8	1.65 (1.33, 2.04)	109/ 67.2
D69 Purpura and other haemorrhagic conditions	1.39 (1.02, 1.86)	57/ 41.0	1.71 (1.37, 2.13)	103/ 61.2
Endocrine, nutritional and metabolic (IV)				
E10 Type 1 diabetes mellitus	1.20 (1.06, 1.37)	289/ 240.8	2.00 (1.74, 2.29)	265/ 135.5
E11 Type 2 diabetes mellitus (+FI)	1.14 (1.04, 1.24)	585/ 516.5	1.49 (1.38, 1.62)	779/ 536.8
E14 Unspecified diabetes mellitus	1.23 (1.01, 1.50)	124/ 100.7	1.91 (1.65, 2.20)	244/ 130.2
E21 Hyperparathyroidism and other disorders of parathyroid gland	1.43 (1.03, 1.95)	50/ 35.0	1.76 (1.44, 2.15)	122/ 70.5
E64 Sequelae of other nutritional deficiencies	1.55 (0.96, 2.40)	26/ 16.8	5.19 (4.24, 6.36)	172/ 33.7
E66 Obesity	1.05 (0.97, 1.13)	821/ 785.8	1.23 (1.15, 1.32)	995/ 826.5
E73 Lactose intolerance	2.33 (1.51, 3.52)	33/ 14.2	8.65 (6.56,11.40)	122/ 14.3
E83 Disorders of mineral metabolism	1.12 (0.74, 1.65)	31/ 27.7	1.71 (1.45, 2.03)	175/ 103.8
E86 Volume depletion (+FI)	1.35 (1.13, 1.60)	159/ 118.2	2.07 (1.93, 2.22)	1010/ 505.8
Mental and behavioural disorders (V)				
F17 Mental and behavioural disorders due to use of tobacco	1.25 (1.07, 1.46)	204/ 163.2	1.51 (1.32, 1.72)	281/ 190.8
F32 Depressive episode (+FI)	1.22 (1.02, 1.44)	162/ 133.2	1.56 (1.39, 1.76)	338/ 221.0
F33 Recurrent depressive disorder (+FI)	1.40 (1.12, 1.73)	104/ 74.5	1.55 (1.37, 1.74)	342/ 225.5
Nervous system (VI)				
G43 Migraine (+FI)	1.22 (1.04, 1.43)	198/ 162.3	1.40 (1.21, 1.62)	224/ 162.8
G47 Sleep disorders (+FI)	1.32 (1.16, 1.49)	316/ 240.7	1.39 (1.27, 1.51)	649/ 478.3
Eye and adnexa (VII)				
H10 Conjunctivitis (+FI)	1.02 (0.88, 1.18)	215/ 211.3	1.51 (1.30, 1.75)	215/ 144.8
H20 Iridocyclitis (+FI)	1.73 (1.32, 2.26)	73/ 42.2	2.24 (1.78, 2.83)	97/ 44.0
Circulatory system (IX)				
I10 Essential (primary) hypertension	1.24 (1.17, 1.31)	1726/1414.3	1.17 (1.11, 1.23)	1950/1751.8
I20 Angina pectoris (+FI)	1.35 (1.25, 1.47)	742/ 553.2	1.33 (1.21, 1.46)	548/ 423.5
I25 Chronic ischaemic heart disease (+FI)	1.31 (1.20, 1.42)	673/ 519.0	1.18 (1.08, 1.29)	592/ 511.8
I26 Pulmonary embolism (+FI)	1.40 (1.11, 1.75)	98/ 70.2	1.73 (1.54, 1.95)	346/ 203.7
I30 Acute pericarditis	1.25 (0.83, 1.82)	33/ 26.5	2.04 (1.51, 2.74)	58/ 28.8
I48 Atrial fibrillation and flutter (+FI)	1.22 (1.11, 1.34)	549/ 452.7	1.20 (1.12, 1.28)	1053/ 898.0
I51 Complications and ill−defined descriptions of heart disease	1.11 (0.75, 1.59)	35/ 31.7	1.60 (1.31, 1.96)	121/ 76.7
I69 Sequelae of cerebrovascular disease	1.31 (1.13, 1.50)	252/ 193.5	1.33 (1.20, 1.47)	436/ 335.5
I70 Atherosclerosis (+FI)	1.58 (1.35, 1.85)	205/ 129.8	1.53 (1.34, 1.75)	262/ 174.0
I71 Aortic aneurysm and dissection	2.02 (1.61, 2.53)	108/ 53.5	1.52 (1.32, 1.75)	237/ 158.8
I74 Arterial embolism and thrombosis	1.16 (0.71, 1.82)	23/ 19.8	2.28 (1.73, 3.00)	70/ 31.2
I80 Phlebitis and thrombophlebitis (+FI)	1.27 (1.09, 1.46)	227/ 179.7	1.84 (1.65, 2.05)	440/ 244.7
Respiratory system (X)				
J01 Acute sinusitis (+FI)	1.17 (0.86, 1.56)	56/ 47.8	1.99 (1.64, 2.40)	141/ 72.2
J03 Acute tonsillitis	1.08 (0.91, 1.26)	182/ 169.2	1.50 (1.31, 1.72)	258/ 174.8
J06 Acute upper resp. infections of multiple & unspecified sites (+FI)	1.09 (0.78, 1.50)	47/ 43.0	1.75 (1.49, 2.05)	188/ 109.3
J09 Influenza due to identified zoonotic or pandemic influenza virus (+FI)	1.17 (0.47, 2.53)	8/ 6.8	2.46 (1.92, 3.14)	89/ 36.8
J18 Pneumonia, organism unspecified (+FI)	1.40 (1.28, 1.53)	642/ 462.8	1.49 (1.40, 1.57)	1519/1059.8
J32 Chronic sinusitis (+FI)	1.57 (1.25, 1.94)	106/ 67.8	1.72 (1.44, 2.07)	148/ 87.5
J45 Asthma (+FI)	1.41 (1.29, 1.54)	619/ 442.7	1.71 (1.57, 1.87)	631/ 381.0
J47 Bronchiectasis (+FI)	1.76 (1.19, 2.54)	38/ 21.7	2.92 (2.39, 3.57)	141/ 49.2
Digestive system (XI)				
K11 Diseases of salivary glands (+FI)	1.33 (0.98, 1.78)	57/ 42.8	1.90 (1.53, 2.36)	105/ 56.2
K21 Gastro−oesophageal reflux disease (+FI)	1.65 (1.48, 1.84)	432/ 263.2	1.60 (1.45, 1.75)	542/ 351.2
K25 Gastric ulcer (+FI)	1.68 (1.42, 1.99)	178/ 106.0	1.78 (1.55, 2.05)	252/ 144.5
K26 Duodenal ulcer (+FI)	0.98 (0.76, 1.26)	73/ 74.2	1.67 (1.35, 2.05)	114/ 69.5
K29 Gastritis and duodenitis (+FI)	1.55 (1.38, 1.74)	384/ 248.7	1.74 (1.57, 1.94)	440/ 260.0
K30 Functional dyspepsia (+FI)	1.64 (1.48, 1.82)	458/ 281.2	1.43 (1.27, 1.62)	322/ 231.8
K35 Acute appendicitis	0.77 (0.66, 0.90)	195/ 251.8	1.76 (1.55, 1.99)	319/ 184.3
K42 Umbilical hernia	1.25 (1.03, 1.51)	135/ 107.8	1.62 (1.41, 1.87)	241/ 151.5
K43 Ventral hernia (+FI)	1.83 (1.54, 2.16)	183/ 100.3	4.17 (3.73, 4.66)	513/ 126.7
K44 Diaphragmatic hernia (+FI)	1.70 (1.50, 1.93)	324/ 191.2	1.57 (1.40, 1.76)	385/ 252.0
K55 Vascular disorders of intestine (+FI)	2.12 (1.26, 3.47)	23/ 10.8	3.30 (2.67, 4.08)	132/ 40.7
K56 Paralytic ileus and obstruction of gut without hernia (+FI)	1.75 (1.40, 2.18)	110/ 62.8	4.43 (4.02, 4.88)	707/ 165.2
K57 Diverticular disease of intestine (+FI)	2.49 (2.27, 2.72)	687/ 281.0	1.23 (1.14, 1.33)	793/ 680.0
K58 Irritable bowel syndrome (+FI)	3.29 (2.95, 3.66)	543/ 167.8	3.57 (3.22, 3.97)	549/ 162.8
K60 Fissure and fistula of anal and rectal regions (+FI)	2.03 (1.73, 2.36)	223/ 110.7	3.89 (3.46, 4.37)	460/ 122.2
K61 Abscess of anal and rectal regions (+FI)	1.97 (1.63, 2.38)	149/ 75.8	3.89 (3.36, 4.50)	293/ 77.2
K64 Haemorrhoids and perianal venous thrombosis	2.00 (1.83, 2.18)	708/ 359.8	1.48 (1.36, 1.61)	666/ 474.3
K65 Peritonitis (+FI)	1.56 (1.11, 2.14)	49/ 31.5	3.83 (3.18, 4.61)	183/ 48.7
K71 Toxic liver disease	1.85 (1.08, 3.06)	21/ 11.3	3.35 (2.37, 4.75)	49/ 14.8
K74 Fibrosis and cirrhosis of liver (+FI)	2.35 (1.55, 3.49)	36/ 15.3	2.26 (1.78, 2.86)	95/ 42.8
K80 Cholelithiasis (+FI)	1.26 (1.15, 1.39)	562/ 447.3	1.29 (1.19, 1.41)	622/ 494.2
K85 Acute pancreatitis (+FI)	2.28 (1.84, 2.80)	129/ 56.8	2.75 (2.39, 3.18)	272/ 101.0
K90 Intestinal malabsorption (+FI)	2.09 (1.55, 2.79)	64/ 30.7	4.26 (3.42, 5.31)	136/ 32.5

prediagnostic — postdiagnostic

Figure 3a: Ulcerative colitis associated diagnoses at the ICD-10 three-character level, first part (Chapters I-XI). Pre-diagnostic OR, odds ratio and 95% CI, confidence intervals and post-diagnostic HR, hazard ratio and 95% CI estimates compared with age-, sex- and municipality-matched controls. Diagnoses meeting the prevalence threshold ($\geq 0.2\%$) with disease-wide significance (Bonferroni correction: $p < 7.90 \times 10^{-6}$) are included. The "(+FI)" symbol indicates that this effect is also significant in the Finnish registry.

	prediag. OR(95% CI)	prediag. events	postdiag. HR(95%CI)	postdiag. events
Skin and subcutaneous tissue (XII)				
L02 Cutaneous abscess, furuncle and carbuncle (+FI)	1.15 (1.02, 1.30)	315/ 273.5	1.66 (1.50, 1.84)	447/ 274.8
L21 Seborrhoeic dermatitis (+FI)	1.36 (0.85, 2.09)	26/ 19.2	3.77 (2.90, 4.90)	91/ 24.5
L23 Allergic contact dermatitis	1.91 (1.48, 2.45)	86/ 45.0	1.90 (1.43, 2.51)	64/ 34.3
L27 Dermatitis due to substances taken internally	1.78 (1.01, 3.01)	19/ 10.7	4.11 (2.87, 5.89)	50/ 12.3
L29 Pruritus (+FI)	1.48 (0.96, 2.20)	31/ 21.0	2.36 (1.88, 2.97)	101/ 43.5
L40 Psoriasis (+FI)	1.54 (1.26, 1.88)	126/ 82.0	2.52 (2.14, 2.96)	206/ 83.5
L50 Urticaria	1.20 (0.98, 1.46)	121/ 101.0	1.65 (1.39, 1.94)	177/ 109.3
L57 Skin changes due to chronic exposure to nonionizing radiation	1.32 (0.97, 1.78)	54/ 40.8	1.54 (1.27, 1.86)	136/ 89.8
L70 Acne	1.88 (1.31, 2.64)	45/ 24.0	5.39 (4.07, 7.12)	93/ 17.5
L71 Rosacea (+FI)	2.15 (1.52, 3.00)	49/ 22.8	3.26 (2.60, 4.07)	118/ 36.8
L88 Pyoderma gangrenosum (+FI)	4.80 (1.65,13.50)	8/ 1.7	20.00 (11.60,34.50)	56/ 2.8
L90 Atrophic disorders of skin	1.04 (0.86, 1.26)	131/ 125.8	1.68 (1.46, 1.94)	238/ 144.2
Musculoskeletal and connective (XIII)				
M02 Reactive arthropathies	1.42 (1.08, 1.84)	72/ 50.8	2.85 (2.26, 3.59)	106/ 37.8
M06 Rheumatoid arthritis	1.29 (1.05, 1.58)	120/ 92.8	1.62 (1.33, 1.97)	129/ 81.0
M07 Psoriatic and enteropathic arthropathies (+FI)	1.81 (1.38, 2.33)	79/ 43.8	10.50 (9.07,12.20)	470/ 46.0
M10 Gout	1.46 (1.17, 1.82)	102/ 69.8	1.50 (1.29, 1.74)	208/ 141.7
M15 Polyarthrosis (+FI)	1.47 (1.12, 1.90)	74/ 50.5	1.99 (1.64, 2.41)	140/ 71.7
M45 Ankylosing spondylitis (+FI)	2.56 (1.85, 3.51)	58/ 22.7	5.48 (4.10, 7.31)	87/ 16.2
M47 Spondylosis	1.36 (1.19, 1.55)	278/ 205.3	1.29 (1.17, 1.43)	440/ 348.0
M50 Cervical disc disorders (+FI)	1.48 (1.28, 1.72)	230/ 155.7	1.20 (1.04, 1.38)	222/ 189.2
M54 Dorsalgia (+FI)	1.28 (1.19, 1.37)	1051/ 831.7	1.39 (1.31, 1.47)	1352/1011.5
M70 Soft tissue disorders related to use, overuse and pressure	1.25 (1.09, 1.44)	256/ 204.8	1.29 (1.16, 1.45)	374/ 294.8
M75 Shoulder lesions (+FI)	1.17 (1.08, 1.26)	870/ 749.0	1.29 (1.21, 1.37)	1157/ 928.8
M76 Enthesopathies of lower limb, excluding foot	1.25 (1.08, 1.45)	219/ 175.2	1.35 (1.19, 1.54)	292/ 219.5
M80 Osteoporosis with pathological fracture (+FI)	1.19 (0.93, 1.51)	86/ 72.2	1.68 (1.49, 1.90)	338/ 204.3
M81 Osteoporosis without pathological fracture (+FI)	1.33 (1.18, 1.49)	358/ 271.2	1.92 (1.79, 2.07)	944/ 506.7
Genitourinary system (XIV)				
N10 Acute tubulo−interstitial nephritis (+FI)	1.18 (0.93, 1.48)	93/ 78.8	1.74 (1.44, 2.10)	139/ 81.0
N17 Acute renal failure (+FI)	1.36 (0.92, 1.98)	35/ 25.7	1.67 (1.45, 1.93)	236/ 143.3
N18 Chronic kidney disease (+FI)	1.31 (1.05, 1.61)	112/ 85.8	1.59 (1.43, 1.78)	397/ 254.0
N19 Unspecified kidney failure (+FI)	1.67 (1.20, 2.28)	52/ 31.2	1.83 (1.53, 2.19)	154/ 85.5
N20 Calculus of kidney and ureter (+FI)	1.25 (1.09, 1.42)	284/ 228.3	1.72 (1.56, 1.90)	493/ 293.3
N21 Calculus of lower urinary tract	1.26 (0.80, 1.91)	27/ 21.5	2.02 (1.55, 2.63)	73/ 36.7
N30 Cystitis (+FI)	1.26 (1.14, 1.38)	549/ 439.0	1.44 (1.35, 1.53)	1130/ 811.5
N82 Fistulae of female genital tract (+FI)	2.07 (0.90, 4.37)	10/ 4.8	3.89 (2.55, 5.94)	35/ 9.2
N83 Noninfl. dis. ovary, fallopian tube, broad ligament (+FI)	1.21 (1.05, 1.40)	229/ 189.5	1.50 (1.32, 1.69)	315/ 216.7
Pregnancy, childbirth and the puerperium (XV)				
O23 Infections of genitourinary tract in pregnancy	0.94 (0.76, 1.15)	110/ 117.5	1.63 (1.36, 1.96)	144/ 90.2
O36 Maternal care for other known or suspected fetal problems	0.99 (0.84, 1.15)	190/ 192.7	1.48 (1.29, 1.70)	252/ 174.3
O72 Postpartum haemorrhage	1.05 (0.96, 1.13)	759/ 727.8	1.17 (1.10, 1.23)	1463/1298.0
O82 Single delivery by caesarean section	1.03 (0.94, 1.14)	506/ 490.0	1.66 (1.51, 1.82)	555/ 346.3
Symptoms, signs and findings (XVIII)				
R00 Abnormalities of heart beat	1.29 (1.09, 1.50)	195/ 152.0	1.36 (1.23, 1.51)	457/ 342.0
R05 Cough (+FI)	1.49 (1.30, 1.70)	279/ 188.2	1.64 (1.48, 1.82)	449/ 280.5
R06 Abnormalities of breathing (+FI)	1.29 (1.17, 1.41)	554/ 432.2	1.47 (1.39, 1.55)	1502/1055.3
R07 Pain in throat and chest (+FI)	1.33 (1.22, 1.46)	576/ 434.3	1.36 (1.27, 1.45)	1166/ 887.3
R10 Abdominal and pelvic pain (+FI)	1.43 (1.36, 1.50)	2132/1538.5	1.97 (1.89, 2.05)	2986/1745.5
R11 Nausea and vomiting (+FI)	1.19 (0.95, 1.49)	97/ 81.3	1.96 (1.79, 2.15)	601/ 313.3
R13 Dysphagia (+FI)	1.42 (1.13, 1.77)	99/ 69.8	1.54 (1.37, 1.73)	351/ 232.7
R15 Faecal incontinence (+FI)	2.08 (1.59, 2.71)	78/ 37.5	2.63 (2.18, 3.17)	157/ 60.8
R21 Rash and other nonspecific skin eruption (+FI)	1.86 (1.23, 2.74)	35/ 18.8	2.23 (1.83, 2.72)	136/ 62.0
R31 Unspecified haematuria (+FI)	1.36 (1.22, 1.51)	440/ 325.7	1.36 (1.23, 1.49)	538/ 406.5
R42 Dizziness and giddiness (+FI)	1.25 (1.09, 1.42)	281/ 226.2	1.26 (1.16, 1.38)	573/ 462.7
R50 Fever of other and unknown origin (+FI)	1.27 (1.09, 1.49)	196/ 154.2	2.01 (1.84, 2.20)	642/ 328.0
R51 Headache (+FI)	1.20 (1.05, 1.37)	273/ 228.2	1.47 (1.33, 1.61)	520/ 363.0
R53 Malaise and fatigue (+FI)	1.20 (1.02, 1.41)	179/ 149.3	1.51 (1.41, 1.63)	861/ 581.8
R63 Symptoms and signs concerning food and fluid intake	1.66 (1.29, 2.10)	89/ 53.8	1.65 (1.47, 1.84)	387/ 239.7
R73 Elevated blood glucose level	1.22 (0.74, 1.95)	22/ 18.0	1.88 (1.50, 2.36)	97/ 52.3
R74 Abnormal serum enzyme levels (+FI)	2.07 (1.51, 2.80)	59/ 28.5	3.03 (2.54, 3.62)	180/ 60.5
R91 Abnormal findings on diagnostic imaging of lung (+FI)	1.36 (1.15, 1.61)	168/ 123.5	1.63 (1.49, 1.79)	553/ 346.3
Injury, poisoning, other external causes (XIX)				
T85 Complications of other internal implants and grafts	1.18 (0.82, 1.65)	42/ 35.7	1.81 (1.45, 2.25)	102/ 57.3



prediagnostic — postdiagnostic

Figure 3b: Ulcerative colitis associated diagnoses at the ICD-10 three-character level, first part (Chapters XI-XIX). Pre-diagnostic OR, odds ratio and 95% CI, confidence intervals and post-diagnostic HR, hazard ratio and 95% CI estimates compared with age-, sex- and municipality-matched controls. Diagnoses meeting the prevalence threshold ($\geq 0.2\%$) with disease-wide significance (Bonferroni correction: $p < 7.90 \times 10^{-6}$) are included. The "(+FI)" symbol indicates that this effect is also significant in the Finnish registry.



Figure 4: Diagnoses associated with CD, Crohn's disease and UC, ulcerative colitis before IBD, inflammatory bowel disease diagnosis. Pre-diagnostic OR, odds ratio compared with post-diagnostic HR, hazard ratio of diagnoses of disease-wide significance for Crohn's disease and Ulcerative colitis. Highly statistically significant diagnoses ($p < 0.001$), with pre-diagnostic effect estimates (OR) at least 1.2 of the post-diagnostic effect estimates (HR) are included. The "(+FI)" symbol indicates that this effect is also significant in the Finnish registry.



Figure 5: Comparison of effect sizes for non-digestive comorbidities in Crohn's (left) and ulcerative colitis (right) as reported by Risteys (Finland) compared to the odds ratios computed from the Danish registry. Points beyond 1000 have estimates which are infinite in the relevant axis, but are included here for completeness.

Supplementary materials

Table S1: Interactive table of effect sizes. **See online supplementary materials.**



Figure S1: Flow diagram of study population.

	Crohn's disease		Ulcerative colitis	
	prediagnostic	postdiagnostic	prediagnostic	postdiagnostic
Infectious and parasitic diseases (I)	0.7%	8.1%	0.0%	5.9%
Neoplasms (II)	0.8%	4.7%	1.6%	2.3%
Blood and certain immune mechanisms (III)	4.3%	21.7%	0.0%	13.0%
Endocrine, nutritional and metabolic (IV)	7.0%	19.3%	0.0%	19.3%
Mental and behavioural disorders (V)	2.9%	14.7%	0.0%	4.4%
Nervous system (VI)	4.2%	4.2%	0.0%	4.2%
Eye and adnexa (VII)	3.1%	21.9%	0.0%	9.4%
Ear and mastoid process (VIII)	0.0%	0.0%	0.0%	0.0%
Circulatory system (IX)	3.5%	12.3%	8.8%	19.3%
Respiratory system (X)	6.0%	20.0%	4.0%	16.0%
Digestive system (XI)	40.0%	60.0%	33.3%	53.3%
Skin and subcutaneous tissue (XII)	3.6%	29.1%	1.8%	23.6%
Musculoskeletal and connective (XIII)	21.6%	19.6%	7.8%	23.5%
Genitourinary system (XIV)	4.9%	23.0%	1.6%	14.8%
Pregnancy, childbirth and the puerperium (XV)	0.0%	3.2%	0.0%	6.3%
Perinatal period (XVI)	0.0%	0.0%	0.0%	0.0%
Congenital diseases (XVII)	0.0%	1.9%	0.0%	0.0%
Symptoms, signs and findings (XVIII)	23.1%	35.4%	9.2%	29.2%
Injury, poisoning, other external causes (XIX)	5.7%	4.6%	0.0%	1.1%

proportion significant

0% 10% 20% 30% 40% 50%

Figure S2: Proportion of significant associations in each ICD-10 Chapter. Significance threshold corrected for multiple testing.